SWP1001
/ Stemirna Therap
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 13, 2023
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer
(clinicaltrials.gov)
- P=N/A | N=24 | Recruiting | Sponsor: Stemirna Therapeutics | Unknown status ➔ Recruiting | Trial completion date: Sep 2022 ➔ Dec 2025 | Trial primary completion date: Sep 2020 ➔ Oct 2024
Enrollment open • Metastases • Trial completion date • Trial primary completion date • Esophageal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
September 28, 2022
A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Stemirna Therapeutics | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor
January 20, 2022
A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1; N=36; Not yet recruiting; Sponsor: Stemirna Therapeutics
Clinical • New P1 trial • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1